move up move left move right move bottom

Janssen CarePath Support Program

Comprehensive support program to help patients start and stay on therapy

Janssen CarePath offers comprehensive patient support focused on:

  • Access tools to help your patients start on the treatment you prescribe, including information on insurance coverage and affordability options

  • Education tools to help keep patients informed about their disease and the importance of staying on treatment to help support their success

  • Adherence tools to help patients stay on therapy through useful tools and reminders


    Business Associate Agreement (BAA)

    Sign and submit this BAA to ensure compliance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and allow Janssen to provide high levels of service.


    Benefits Investigation Form (BIF)

    Submit a BIF for each patient for whom you would like to complete an assessment of eligibility and coverage for XARELTO®. You can also use this form to request assistance with the prior authorization process for XARELTO®.


    Provider Portal

    Use the provider portal with real-time 24-hour access to submit benefits investigation requests electronically and review the status of your Janssen CarePath patients online.

  • Janssen CarePath Savings Program for XARELTO®

    • Eligible patients with an approved chronic indication for XARELTO® (10 mg, 15 mg or 20 mg)

    • Eligible commercially insured patients can have as little as a $10 co-pay per month for their XARELTO® medication costs with up to $3,400 maximum program benefit per calendar year. Subject to a monthly limit. Not valid for patients using Medicare, Medicare Part D, Medicaid, or other government-funded program.

    For eligibility requirements, visit Janssen CarePath or call 877-CarePath (877-227-3728).

  • Other Resources

    The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, nonprofit organization that is committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. To see if they might qualify for assistance, please have your patient contact a JJPAF program specialist at 1-800-652-6227 (9 am to 6 pm ET) or visit the foundation website at






Indication and Important saftey Information


  • Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
  • Treatment of deep vein thrombosis (DVT).
  • Treatment of pulmonary embolism (PE).
  • Reduction in the risk of recurrence of DVT and/or PE in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery.